Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 5
2021 6
2022 7
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, Lavi N, Ganzel C, Luttwak E, Chubar E, Rouvio O, Vaxman I, Pasvolsky O, Ballan M, Tadmor T, Nemets A, Jarchowcky-Dolberg O, Shvetz O, Laiba M, Shpilberg O, Dally N, Avivi I, Weiner A, Amit I. Cohen YC, et al. Among authors: luttwak e. Nat Med. 2021 Mar;27(3):491-503. doi: 10.1038/s41591-021-01232-w. Epub 2021 Feb 22. Nat Med. 2021. PMID: 33619369 Free PMC article.
Lymphoproliferative disease detected by breast cancer screening.
Luttwak E, Segman Y, Saban M, Gutwein O, Avivi I, Perry C, Filiavich A, Sarid N. Luttwak E, et al. J Med Screen. 2022 Dec;29(4):255-259. doi: 10.1177/09691413221109988. Epub 2022 Jul 12. J Med Screen. 2022. PMID: 35818749
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Beyar Katz O, Perry C, Grisariu-Greenzaid S, Yehudai-Ofir D, Luttwak E, Avni B, Zuckerman T, Sdayoor I, Stepensky P, Ringelstein-Harlev S, Bar-On Y, Libster D, Sharvit L, Amit O, Greenbaum U, Gold R, Herishanu Y, Benyamini N, Avivi I, Ram R. Beyar Katz O, et al. Among authors: luttwak e. Eur J Haematol. 2023 Jul;111(1):63-71. doi: 10.1111/ejh.13968. Epub 2023 Apr 10. Eur J Haematol. 2023. PMID: 36964939
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma.
Leithner D, Flynn JR, Devlin SM, Mauguen A, Fei T, Zeng S, Zheng J, Imber BS, Hubbeling H, Mayerhoefer ME, Bedmutha A, Luttwak E, Corona M, Dahi PB, Luna de Abia A, Landego I, Lin RJ, Palomba ML, Scordo M, Park JH, Tomas AA, Salles G, Lafontaine D, Michaud L, Shah GL, Perales MA, Shouval R, Schöder H. Leithner D, et al. Among authors: luttwak e. J Hematol Oncol. 2024 Apr 23;17(1):21. doi: 10.1186/s13045-024-01540-x. J Hematol Oncol. 2024. PMID: 38649972 Free PMC article.
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge.
Bronstein Y, Gat R, Levi S, Cohen YC, Luttwak E, Benyamini N, Shragai T, Vitkon R, Neaman M, Eilaty N, Levi M, Trestman S, Perry C, Herishanu Y, Avivi I. Bronstein Y, et al. Among authors: luttwak e. Cancer Cell. 2022 Jun 13;40(6):578-580. doi: 10.1016/j.ccell.2022.04.015. Epub 2022 Apr 21. Cancer Cell. 2022. PMID: 35477028 Free PMC article. No abstract available.
Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?
Cohen D, Perry C, Hazut-Krauthammer S, Kesler M, Herishanu Y, Luttwak E, Even-Sapir E, Avivi I. Cohen D, et al. Among authors: luttwak e. Cancers (Basel). 2022 Jan 31;14(3):750. doi: 10.3390/cancers14030750. Cancers (Basel). 2022. PMID: 35159016 Free PMC article.
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
Ghione P, Ahsanuddin S, Luttwak E, Varela SB, Nakajima R, Michaud L, Gupta K, Navitski A, Straus D, Palomba ML, Moskowitz A, Noy A, Hamlin P, Matasar M, Kumar A, Falchi L, Yahalom J, Horwitz S, Zelenetz A, Younes A, Salles G, Schöder H, Joffe E. Ghione P, et al. Among authors: luttwak e. Haematologica. 2024 Jan 1;109(1):200-208. doi: 10.3324/haematol.2022.282643. Haematologica. 2024. PMID: 37646672 Free PMC article.
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I, Perry C, Segman Y, Amit O, Bar-On Y, Katz OB, Gold R, Ribakovsky E, Avigdor A, Vainstein V, Goldschmidt N, Ringelstein-Harlev S, Horowitz NA, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Vezker M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Luttwak E, Herishanu Y, Ram R. Avivi I, et al. Among authors: luttwak e. Ann Hematol. 2022 Apr;101(4):755-762. doi: 10.1007/s00277-021-04749-9. Epub 2022 Jan 27. Ann Hematol. 2022. PMID: 35083525
22 results